- Home
- APVO vs RNAZ Comparison
APVO vs RNAZ Comparison
Compare APVO & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- RNAZ
- Stock Information
- Founded
- APVO 2016
- RNAZ 2016
- Country
- APVO United States
- RNAZ United States
- Employees
- APVO N/A
- RNAZ N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- RNAZ Health Care
- Exchange
- APVO Nasdaq
- RNAZ Nasdaq
- Market Cap
- APVO 4.4M
- RNAZ 4.9M
- IPO Year
- APVO N/A
- RNAZ 2021
- Fundamental
- Price
- APVO $4.50
- RNAZ $3.62
- Analyst Decision
- APVO Strong Buy
- RNAZ Strong Buy
- Analyst Count
- APVO 1
- RNAZ 1
- Target Price
- APVO $296.00
- RNAZ $99.00
- AVG Volume (30 Days)
- APVO 485.4K
- RNAZ 30.4K
- Earning Date
- APVO 11-07-2024
- RNAZ 11-14-2024
- Dividend Yield
- APVO N/A
- RNAZ N/A
- EPS Growth
- APVO N/A
- RNAZ N/A
- EPS
- APVO N/A
- RNAZ N/A
- Revenue
- APVO N/A
- RNAZ N/A
- Revenue This Year
- APVO N/A
- RNAZ N/A
- Revenue Next Year
- APVO N/A
- RNAZ $233.33
- P/E Ratio
- APVO N/A
- RNAZ N/A
- Revenue Growth
- APVO N/A
- RNAZ N/A
- 52 Week Low
- APVO $3.65
- RNAZ $6.31
- 52 Week High
- APVO $399.60
- RNAZ $264.00
- Technical
- Relative Strength Index (RSI)
- APVO 35.34
- RNAZ 23.15
- Support Level
- APVO $3.65
- RNAZ $6.63
- Resistance Level
- APVO $4.78
- RNAZ $8.46
- Average True Range (ATR)
- APVO 1.95
- RNAZ 1.04
- MACD
- APVO -0.70
- RNAZ -0.25
- Stochastic Oscillator
- APVO 7.55
- RNAZ 1.65
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.